On 28, FUSONPHARMA announces that its non-public offering A Shares plan has passed the audit of China Securities Regulatory Commission on January 27.

According to the plan, this time FUSONPHARMA plans to privately issue no more than 46 million shares and no less than 20 million A Shares, and the collected capital will be used for recombining human insulin industrialization (raw materials + preparations), demonstration project of artesunate high technology industrialization and production base of vitro diagnostic products and another three projects, and the net amount of the collected capital will not exceed the total amount of project investment about RMB 635,488,000.
Fosun Pharmaceutical Group pays attention to talent echelon construction and employee career growth. We will highly associate employee individual development with enterprise development to the utmost and highly integrate enterprise progress and individual value improvement together, in accordance with the talent management strategy of “Pursue high harmony and unity about individual success and enterprise development”.

With rapid development of the Group, how to continuously provide necessary talents for company development has become a serious problem to be solved. Since 2009, the Group has established the training development center with training management and employee development as principal functions, it unites with training teams of member enterprise, combines employee development requirements with the enterprise and from talent evaluation and selection to training, it has formed a whole set of comprehensive employee training system.